CRBP · Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Market Cap
50.18M
52 Wk Range
$2.42 - $12.88
Previous Close
$2.44
Open
$2.43
Volume
1,382,981
Day Range
$2.01 - $2.48
Enterprise Value
-54.86M
Cash
115.3M
Avg Qtr Burn
-21.24M
Insider Ownership
1.16%
Institutional Own.
83.72%
Qtr Updated
Sep 30th 2026
